| |
<<In light of the FDA's
decision to approve a generic version of Clozaril(R) by IVAX
Corporation, Novartis Pharmaceuticals Corporation, manufacturer of
Clozaril tablets, reemphasized today its commitment to the safe and
effective treatment of therapy-resistant schizophrenia. >>
yes, you are right: we could more easily extrapolate, assuming
we could find the numbers. but, i DID like the apparent need
felt by novartis to temper the ivax release with the above iteration.
i find this demonstrated concern for shareholders all the more
GLARING as a clear counterpoint to the ivax model...ironic,
isn't it? especially, in light of the feigned ( or genuine? even
more appalling...) ignorance by IR when you asked them about
immunex. and STILL, not a whisper to that end, or to the prospects
for paclitaxel, should they remain somehow viable.
by the way, any further guidance in that regard, from your fda
connection? i assume, of course, frosty, has NOT responded with
the alacrity i had hoped: i give him the benefit of the doubt,
FOR NOW, and fully expect a reply forthcoming, however.
perhaps he is saving up for the REAL news before he replies???
it WOULD be nice....
randy
ps
thanks for the welcome. |
|
